

Supplementary Table S3. Baseline Characteristics and Response to Ipilimumab in 19 Patients Previously Treated with TIL ACT

Baseline Characteristics	
Mean age in years	52
Female – no. (%)	6 (32%)
ECOG performance status – no. (%)	
0	14 (74%)
≥ 1	5 (26%)
M stage – no (%)	
M0	0
M1a	3 (16%)
M1b	2 (11%)
M1c	14 (74%)
Lactate dehydrogenase above normal – no. (%)	9 (46%)
CNS metastases at baseline – no. (%)	1 (5%)
Previous therapy for metastatic disease – no. (%)	19 (100%)
Previous IL-2 therapy – no. (%)	19 (100%)
Response to Ipilimumab	
No. of patients	19
Best overall response rate[†] to IPI (CR + PR)	3 (16%)
Best overall response[†] to IPI – no. (%)	
Complete response (CR)	3 (16%)
Partial response (PR)	0
Non-response (SD + PD)	16 (84%)

Supplementary Table S3. Baseline Characteristics and Response to Ipilimumab in 19 Patients Previously Treated with TIL ACT

[†] According to RECIST v1.1 guidelines

Abbreviations: IPI, ipilimumab; ECOG, Eastern Cooperative Oncology Group; M stage, metastasis stage; CNS, central nervous system; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; IL-2, interleukin-2